NCT05962892 A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma
| NCT ID | NCT05962892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Friendship Hospital |
| Condition | Papillary Thyroid Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2024-02-01 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.
Eligibility Criteria
Inclusion Criteria: ①≥18 years old; ② Obtain informed consent; ③ Ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ PTC was confirmed by fine needle puncture pathology; ⑥ Patients who do not meet Article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation Exclusion Criteria:① Pregnant or lactating patients; ② Patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ Patients who cannot tolerate surgery; ④ Patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05962892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Papillary Thyroid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05962892 currently recruiting?
Yes, NCT05962892 is actively recruiting participants. Contact the research team at sonoshixq@ccmu.edu.cn for enrollment information.
Where is the NCT05962892 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05962892 clinical trial?
NCT05962892 is sponsored by Beijing Friendship Hospital. The trial plans to enroll 600 participants.